Difference between revisions of "Hepatic Neoplasia"
Jump to navigation
Jump to search
| Line 1: | Line 1: | ||
{{Unfinished}} | {{Unfinished}} | ||
| − | Primary hepatic tumours are rare | + | * Primary hepatic tumours are rare (less than 1.5% of all canine tumours and 1.0-2.9% of all feline tumours) * However, the liver is a common site of metastatic tumours due to the rich blood supply (hapatic portal vein and hepatic artery) |
| − | * [[Liver Proliferative - Pathology #Hepatocytic|Hepatocellular carcinoma]] | + | * In dogs, metastasis to the liver is 2.5 times more likely than primary neoplasia |
| − | * [[Liver Proliferative - Pathology #Cholangiocellular|Cholangiocellular carcinoma]] | + | * In cats, primary hepatobillary tumours are more frequent than metastatic tumours |
| − | * Gall bladder carcinoma | + | * Malignant tumours are more common in dogs |
| − | * [[Liver Proliferative - Pathology #Haemangiosarcoma|Haemangiosarcoma]] | + | * Benign tumours are more common in cats |
| − | * Mast cell tumour | + | * Malignant primary tumours include: |
| − | * Hepatic carcinoids | + | ** [[Liver Proliferative - Pathology #Hepatocytic|Hepatocellular carcinoma]] |
| + | ** [[Liver Proliferative - Pathology #Cholangiocellular|Cholangiocellular carcinoma]] | ||
| + | ** Gall bladder carcinoma | ||
| + | ** [[Liver Proliferative - Pathology #Haemangiosarcoma|Haemangiosarcoma]] | ||
| + | ** Mast cell tumour | ||
| + | ** Hepatic carcinoids (neuroendocrine) | ||
Benign tumours include: | Benign tumours include: | ||
| − | * [[Liver Proliferative - Pathology #Hepatocytic|Hepatocellular adenoma]] (hepatoma) | + | ** [[Liver Proliferative - Pathology #Hepatocytic|Hepatocellular adenoma]] (hepatoma) |
| − | * [[Liver Proliferative - Pathology #Cholangiocellular|Cholangiocellular adenoma]] | + | ** [[Liver Proliferative - Pathology #Cholangiocellular|Cholangiocellular adenoma]] |
| − | * Gall bladder adenoma | + | ** Gall bladder adenoma |
| − | Note: Distinction must be made between all hepatic tumours and benign nodular hyperplasia frequently observed in the canine. The most significant primary tumours in the dog are hepatomas, hepatocellular and cholangiocellular carcinomas and hepatic carcinoids. Hepatocellular carcinomas and cholangiocarcinomas are the most significant in cats. | + | Note: Distinction must be made between all hepatic tumours and benign nodular hyperplasia frequently observed in the older canine. The most significant primary tumours in the dog are hepatomas, hepatocellular and cholangiocellular carcinomas and hepatic carcinoids. Hepatocellular carcinomas and cholangiocarcinomas are the most significant in cats. |
Revision as of 08:33, 12 August 2009
 |
This article is still under construction. |
- Primary hepatic tumours are rare (less than 1.5% of all canine tumours and 1.0-2.9% of all feline tumours) * However, the liver is a common site of metastatic tumours due to the rich blood supply (hapatic portal vein and hepatic artery)
- In dogs, metastasis to the liver is 2.5 times more likely than primary neoplasia
- In cats, primary hepatobillary tumours are more frequent than metastatic tumours
- Malignant tumours are more common in dogs
- Benign tumours are more common in cats
- Malignant primary tumours include:
- Hepatocellular carcinoma
- Cholangiocellular carcinoma
- Gall bladder carcinoma
- Haemangiosarcoma
- Mast cell tumour
- Hepatic carcinoids (neuroendocrine)
Benign tumours include:
- Hepatocellular adenoma (hepatoma)
- Cholangiocellular adenoma
- Gall bladder adenoma
Note: Distinction must be made between all hepatic tumours and benign nodular hyperplasia frequently observed in the older canine. The most significant primary tumours in the dog are hepatomas, hepatocellular and cholangiocellular carcinomas and hepatic carcinoids. Hepatocellular carcinomas and cholangiocarcinomas are the most significant in cats.
Signalment
- Hepatic carcinoma occurs most often in male dogs over 10 years old
- Cholangiocellular carcinoma occurs more commonly in female cats
Description
Carcinogens and toxins for example nitrosamines can induce hepatic tumours in an experimental environment.